1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
ZIM Laboratories Limited

ZIM Laboratories Limited

ZIMLAB.NS
ZIM Laboratories LimitedIN flagNational Stock Exchange of India
119.57
INR
-2.44
- -
6.40BMarket Cap

Total Valuation

ZIM Laboratories Limited carries a market capitalization of 6.40B, placing it among publicly traded companies globally. Its enterprise value stands at 3.92B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.40B
Enterprise Value3.92B

Share Statistics

ZIM Laboratories Limited currently has 53.50M shares outstanding.

Shares Outstanding53.50M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

ZIM Laboratories Limited trades at a trailing price-to-earnings ratio of 50.21. The price-to-sales ratio is 0.78, and the price-to-book ratio stands at 1.28.

PE Ratio50.21
PS Ratio0.78
PB Ratio1.28
P/TBV Ratio1.15
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, ZIM Laboratories Limited trades at an EV/EBITDA multiple of 39.05 and an EV/FCF ratio of 41.74. The EV/Sales ratio of 1.05 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 39.05 provides insight into valuation relative to core operating earnings.

EV / Sales1.05
EV / EBITDA39.05
EV / EBIT39.05
EV / FCF41.74

Financial Position

ZIM Laboratories Limited maintains a current ratio of 1.45, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.68, indicating elevated leverage, while an interest coverage ratio of 0.76 demonstrates limited ability to service its debt obligations.

Current Ratio1.45
Quick Ratio0.15
Debt / Equity42.68
Debt / EBITDA12.60
Interest Coverage0.76

Financial Efficiency

ZIM Laboratories Limited posts a return on equity of 2.62 and a return on invested capital of 1.78.

Return on Equity (ROE)2.62
Return on Assets (ROA)1.15
Return on Invested Capital (ROIC)1.78
Return on Capital Employed (ROCE)4.41
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.83

Taxes

Over the trailing twelve months, ZIM Laboratories Limited has paid 23.75M in income taxes, reflecting an effective tax rate of 28.91.

Income Tax23.75M
Effective Tax Rate28.91

Stock Price Statistics

ZIM Laboratories Limited's stock has gained approximately 7.81785% over the past 52 weeks. The 50-day moving average sits at 106.49, while the 200-day moving average is 80.15.

Beta (5Y)N/A
52-Week Price Change7.81785%
50-Day Moving Average106.49
200-Day Moving Average80.15
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, ZIM Laboratories Limited generated 3.74B in revenue and converted that into 58.38M in net income, yielding earnings per share of 1.20. EBITDA reached 100.32M, while operating income came in at 100.32M.

Revenue3.74B
Gross Profit2.09B
Operating Income100.32M
Pretax Income82.13M
Net Income58.38M
EBITDA100.32M
EBIT100.32M
Earnings Per Share (EPS)1.20

Balance Sheet

ZIM Laboratories Limited holds 278.02M in cash and equivalents against 1.26B in total debt, resulting in a net debt position of 976.99M. Total book value stands at 2.28B, with working capital of 854.16M providing operational flexibility.

Cash & Cash Equivalents278.02M
Total Debt1.26B
Net Debt976.99M
Equity (Book Value)2.28B
Book Value Per Share46.93
Working Capital854.16M

Margins

ZIM Laboratories Limited operates with a gross margin of 55.83, reflecting its pricing power and cost economics. The operating margin of 2.68 and net profit margin of 1.56 provide insight into operational efficiency.

Gross Margin55.83
Operating Margin2.68
Pretax Margin2.19
Profit Margin1.56
EBITDA Margin2.68

Stock Splits

ZIM Laboratories Limited's most recent stock split took place on December 22, 2022 with a 1:3 split ratio.

Last Split Date12/22/2022
Split Ratio1:3

Scores

ZIM Laboratories Limited posts an Altman Z-Score of 2.24, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.24